Blood test timing could unlock secrets of advanced breast cancer
NCT ID NCT07681323
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study looks at how the timing of a blood test that detects tumor DNA (ctDNA) affects understanding of prognosis and treatment choices in people with advanced HR+/HER2- breast cancer. Researchers will follow 400 participants to see how ctDNA levels and gene mutations relate to survival and treatment response. The goal is to learn whether earlier or later testing provides better information for guiding care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors better predict outcomes and tailor treatments for advanced breast cancer patients.
What could go wrong
This is an observational study, so it does not test a new treatment. Results may not change practice without further trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral Vinorelbine for Advanced Breast Cancer (NCT06500494)
- EMBER Trial: Imlunestrant for ER+ Breast Cancer NCT04188548
- Electroacupuncture to Prevent Chemo Nerve Damage NCT07644533
- Deruxtepruzumab for Advanced Breast Cancer – NCT07670182
- Breast Cancer Treatment Study (NCT03417115)
- Radiotherapy-Sensitized Immunotherapy for Advanc NCT06776861
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, 100100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact